Gregory Lovins
Analyst · Robert W. Baird. Please proceed
Thanks Mitch, I appreciate that, and I’m really excited to be in the role and I’m looking forward to continue in partnering with you and the rest of our leadership as well. And hello to everybody in the call, and with that let we jump into the quarter. As Mitch mentioned, we delivered another solid quarter with earnings coming in ahead of our expectations. We grew sales by 7%, excluding currency and 3% on an organic basis and we delivered a 20% increase in adjusted earnings per share. Strong operating performance and a lower tax rate both contributed to the year-on-year change. Currency translation reduced reported sales by about 1% in the second quarter, was an approximately $0.02 negative impact to EPS. Our adjusted operating margin in the second quarter of 10.8% was up slightly versus the prior-year, as productivity and higher volumes more than offset higher employee related costs and a modest headwind from the net impact of pricing and raw material costs. Productivity gains this quarter included approximately $15 million of net restructuring savings, most of which benefited the RBS segment. Our adjusted tax rate was 26% in the quarter, down from 30% in the first quarter and reflective of our revised expectation of 28% for the full year. The reduction to the full-year tax rate is driven by continued favorable geographic income mix and a net favorability from discrete items. We now expect our sustainable tax rate to be in the upper 20s large reflecting that continued favorable geographic mix. Year-to-date we’ve generated free cash flow of $93 million, $59 million less than the same period last year as 2016 included a significant improvement in our working capital ratio. While we’ve largely sustained last year’s working capital efficiency gain, the cash flow benefit from that improvement doesn’t repeat. Higher capital spending also contributed to lower free cash flow relative to prior year, and we continue to expect free cash flow conversion for the year of nearly 100% of GAAP net income. Our balance sheet remains strong. We have ample capacity to invest in the business including funding our M&A strategy, as well as continuing to return cash to shareholders in a disciplined manner. Our net note in late April released our quarterly dividend rate by 10%, and received authorization from our board to repurchase an additional $650 million of stock. In the quarter, we repurchased approximately 400,000 shares at an aggregate cost of $36 million, and our share count declined modestly. We also paid $40 million in dividends in the quarter. On the acquisition front, we closed the previously announced Yongle deal in June, and the integration of that business is underway. While we expect this acquisition to have an immaterial impact on EPS for the full year, one-time transition cost will have a meaningful impact on margins in the IHM segment in the third quarter. As Mitch mentioned, we also acquired Finesse Medical, an Ireland based wound care manufacture with approximately €15 million in annual revenue. And we continue to expect that Mactac will contribute close to $0.10 of EPS improvement in 2017. And we expect the newly completed deals to contribute more than $0.10 to EPS next year. Following the acquisitions, our net debt-to-EBITDA ratio temporarily increased, and is now closer to the high end of our target range. With that said, we have ample capacity to continue pursuing our disciplined capital allocation strategy. So let me turn to the segment results for the quarter. Label and Graphic Material sales were up 7% excluding currency, bolstered by the Mactac and Hanita acquisitions. Organic sales growth was 2% in the quarter, with high-value categories up mid-single digits and modest growth in base categories. As Mitch indicated, this represented a moderation of our performance over the last few quarters, largely reflecting timing effects, including the Q1 benefit from the pull forward of sales to the price increase in China, which we discussed last quarter, as well as the timing of various holidays between quarters and inventory destocking related to implementation of the new goods and services tax in India. And looking at the regions, in North America, we grew in low single digits, which we believe was due to modest pickup in demand and some share gain. This represents an improvement of our trend from previous quarters. Growth in emerging markets moderated to a low single-digit rate in the quarter as well, largely reflecting the timing issues that I outlined as well as the challenging prior-year comparison for Eastern Europe. So while we did see some softening of our growth rate and pockets of our business in Q2, we are confident in the return to roughly 4% organic growth for this segment in the third quarter. LGM’s adjusted operating margin of 13.6% was unchanged from a relatively high level we saw last year, as the benefits from productivity and higher volume offset higher employee-related cost in a modest negative net impact from price and raw material costs. As we anticipated, aggregate commodity costs increased sequentially than ease towards the end of the quarter on a global basis. Of course, we see raw material costs trend to differ across regions and individual commodities, and we continue to monitor these movements within each market and adjust our prices as necessary. So let me shift to retail Branding and Information Solutions. RBS sales were up 6% organically, driven largely by the performance athletic in Premium Fashion segments within the base business, as well as strong growth of RFID with RFID products up more than 20% in the quarter. We continue to see volume growth outpace apparel unit imports and at the same time the headwind from strategic price actions we started implementing over a year ago, which was designed to improve competitiveness in our base business are largely behind us. RBS' operating margin improvement reflected the benefits of productivity initiatives and higher volume, which are partly offset by higher employee-related costs. We anticipate continued margin expansion in the back half of the year as the team continues to execute the business model transformation, and we benefit from the reduction and amortization that we’ve previously discussed. Sales in our Industrial and Healthcare Materials segment were up 10% excluding currency. While sales were flat on an organic basis, they actually came in better than expected, due largely to the strength in industrial categories, which were up low double digits for the quarter. Our operating margin declined in this business largely as expected due primarily to the decline in healthcare categories, including the impact of certain contractual payments we received last year that did not repeat. Acquisition integration costs in a modest negative effect in the net impact of price from raw material cost consistent with what we’re seeing in LGM also contributed to the decline. As I mentioned earlier, acquisition related costs such as inventory step up, amortization and other transition cost related to the Yongle acquisition will temporarily reduce IHM margins in the back half of this year. We’re focused on improving our profitability in this segment, while investing to support growth and expect to see operating margin expand to LGM’s level or better over the long term. So let me now turn to the balance for the outlook of the year. We have raised the midpoint of our guidance for adjusted earnings per share by $0.25 to an updated range of $475 million to $490 million. Roughly $0.10 of this increase reflects stronger operating results and $0.15 comes from the combination of a lower tax rate and a modest net benefit from currency and share count. We outlined some of the key contributing factors to our EPS guidance on slide 9 of our supplemental presentation materials. Focusing on the factors that have changed from our previous outlook, we now expect reported sales growth of 7% to 8% for the full year, reflecting the impact of Yongle and Finesse acquisitions and a smaller currency headwind. At recent foreign exchange rates, we estimate the currency translation will reduce net sales by less than 0.5%, and reduce pre-tax earnings by roughly $4 million. We now also expect incremental restructuring savings from $45 million to $50 million at the high-end of the previously communicated range. And as discussed, we’re now expecting a tax rate of approximately 28% compared to our previous assumption of 30%, again reflecting our new anticipated annual run rate. And we expect average shares outstanding, assuming dilution of approximately 89.5 million to 90 million shares. Our other key assumptions remain unchanged from what shared last quarter. So to wrap up, we’re pleased to report another solid quarter of continued progress against our long-term strategic and financial objectives. And with that, we’ll now open the call for your questions.